Keywords: Biosimilars, Stada Arzneimiittel, Gedeon Richter, Rituxumab, Trasturzumab, Roche, Europe, CIS, Herceptin, Rituxan, MabThera

Stada Arz and Richter link up to develop and market two biosimilars: rituximab and trastuzumab

Article | 01 September 2011

Print This

Germany’s Stada Arzneimittel (SAZ: GR) and Hungarian group Gedeon Richter (BDP: RICHTER) have signed two separate license and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in